Safety and immunogenicity of trivalent inactivated influenza vaccine in adults 60 years of age and older: a phase II, a randomized, comparative trial in Kazakhstan

Safety and immunogenicity of trivalent inactivated influenza vaccine in adults 60 years of age and older: a phase II, a randomized, comparative trial in Kazakhstan

Background The study was aimed at comparative evaluation of seasonal influenza vaccine RIBSP versus commercial vaccine VAXIGRIP® for immunogenicity and safety in the course of clinical trial phase II on healthy subjects up to 60 years. Methods The trial involved 150 subjects in randomized 2:1 groups...

Full description

Bibliographic Details
Main Authors: Gulbanu Sarsenbayeva, Timur Issagulov, Markhabat Kassenov, Ruslan Abitay, Mukhit Orynbayev, Marina Stukova, Maria Pisareva, Timur Davlyatshin, Kutumbetov Lespek, Berik Khairullin
Format: Article
Language:English
Published: Taylor & Francis Group 2020-08-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
influenza virus
humoral immunity
vaccines/vaccines strains
Online Access:http://dx.doi.org/10.1080/21645515.2019.1705691

Internet

http://dx.doi.org/10.1080/21645515.2019.1705691

Similar Items